KLK3 and prostate carcinoma: Primary endpoint of ARTO trial may seem questionable, but PSA response has been tested as a surrogate endpoint after radical treatment and showed to be a strong prognostic biomarker for biochemical progression-free survival (bPFS), Prostate Cancer specific survival (PCSS), and OS [27].